Physician profile
Yuan Chen
NPI 1811900186
$5,378.51
in general payments reported to CMS, 2019-2025
40 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $621 · 2021: $1,212 · 2022: $990 · 2023: $599 · 2024: $340 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,223.40 | 2021-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $726.44 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $502.57 | 2019-2021 | |
| Pfizer INC. | $472.33 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $239.28 | 2022 | |
| Nevro Corp. | $166.56 | 2019-2024 | Senza |
| Horizon Therapeutics Plc | $158.11 | 2019-2022 | |
| Saol Therapeutics INC. | $144.29 | 2020-2022 | |
| Ibsa Pharma INC. | $131.44 | 2023-2025 | Tirosint, Licart, Tirosint |
| Biodelivery Sciences International, INC. | $123.78 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $120.27 | 2021 | |
| Amneal Pharmaceuticals LLC | $111.24 | 2022-2023 | Lioresal (Baclofen), Lyvispah |
| Zyla Life Sciences, INC. | $107.47 | 2019-2020 | |
| Lilly USA, LLC | $103.26 | 2021-2023 | Reyvow, Emgality |
| Integra Lifesciences Corporation | $98.60 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.